GVHD
Advertisement
PTCy/Tac/MMF and tacrolimus plus methotrexate provided similar rates of graft-versus-host disease prevention.
In a recent study, researchers from the Hope National Medical Center in Duarte, California, evaluated the safety and ...
Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved ...
In a phase 2 trial, presented at the 64th ASH Annual Meeting and Exposition, researchers compared itacitinib monotherapy ...
For years, the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic cell ...
In a meta-analysis presented at the 2022 American Society of Clinical Oncology Annual Meeting, researchers evaluated ...
According to research presented at the 2022 American Society of Clinical Oncology Annual Meeting, graft-versus-host ...
Hispanic patients had a significantly lower cumulative incidence of chronic graft-versus-host disease (GVHD) than ...
The first-in-human, phase I clinical trial of ADI-001, an allogeneic gamma delta chimeric antigen receptor (CAR) T-cell ...
The recently FDA-approved ruxolitnib should be utilized more in the treatment of chronic steroid-refractory ...
Seeking to improve early detection of chronic graft-versus-host disease (cGVHD), Ankit Shah and colleagues tested if ...
In a poster presented at the Transplantation & Cellular Therapy (TCT) 2022 Tandem Meetings from the American Society ...
There is a lack of data on cardiac toxicity related to post-transplant cyclophosphamide (PTCY) for graft-versus-host ...
Patients receiving haploidentical hematopoietic cell transplantation (haplo-HCT) often develop cytokine release syndrome ...
Acute graft-versus-host disease is a leading cause of mortality after allogeneic hematopoietic stem cell transplantation ...
Although allogeneic hematopoietic cell transplant (HCT) can cure hematologic disease, the treatment may result in ...
This week on DocWire, we covered the latest breaking research from the American Society of Hematology (ASH) 2021 Annual ...
Adoptive immunotherapy with CD4+/CD25/+FOXP3+ regulatory T cells (Tregs) and conventional T cells (Tcons) has been used ...
Updated results from a real-world analysis confirm that ruxolitinib is an effective treatment option for patients with ...
The combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.